<?xml version="1.0" encoding="UTF-8"?>
<p id="Par108">Phase 1 studies are currently in progress to evaluate the safety and immunogenicity of a vaccine against PIV; phase 2 studies evaluating the efficacy of the new agent DAS-181 against PIV in immunocompromised patients are ongoing [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
